argenx SE (EBR:ARGX)
665.60
-11.60 (-1.71%)
Apr 28, 2026, 5:35 PM CET
argenx SE Revenue
In the year 2025, argenx SE had annual revenue of $4.24B USD with 88.44% growth. argenx SE had revenue of $1.31B in the quarter ending December 31, 2025, with 73.04% growth.
Revenue
$4.24B
Revenue Growth
+88.44%
P/S Ratio
11.47
Revenue / Employee
$2.27M
Employees
1,863
Market Cap
41.39B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.24B | 1.99B | 88.44% |
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| Financière de Tubize | 13.26K |
| Onward Medical | 5.41M |
| Hyloris Pharmaceuticals | 8.83M |
| European Medical Solutions | 52.80M |
| Celyad Oncology | 21.00K |
| BioSenic | -2.39M |
| Oxurion NV | 2.00K |
argenx SE News
- 7 days ago - Noteworthy ETF Outflows: IBB, REGN, ARGX, INSM - Nasdaq
- 9 days ago - argenx (ARGX) Reveals New Vyvgart Data at 2026 AAN Annual Meeting - GuruFocus
- 10 days ago - argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - GlobeNewsWire
- 11 days ago - Wedbush Reaffirms ARGX, NUVB, FENC At Outperform; Lifts PT For Kiniksa; Keeps NVCR At Neutral - Nasdaq
- 26 days ago - Oppenheimer Lowers Price Target for ARGX, Reiterates Outperform Rating | ARGX Stock News - GuruFocus
- 27 days ago - Goldman Sachs Highlights Argenx (ARGX) as Prime Growth Opportunity - GuruFocus
- 5 weeks ago - eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency - Business Wire
- 7 weeks ago - argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - GlobeNewsWire